SCHEMBL3857926

SCHEMBL3857926

CC(CCCO)NC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.39
TAS1R1 Q7RTX1 2/20 0.39
TAS1R2 Q8TE23 2/20 0.39
CYP2C19 P33261 3/20 0.36
CYP2C9 P11712 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP2D6 P10635 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
POLB P06746 1/20 0.33
PTPN1 P18031 1/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
HPGD P15428 1/20 0.33
CAMK2A Q9UQM7 1/20 0.33
MLYCD O95822 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CYP1A2 P05177 1/20 0.31
GPR84 Q9NQS5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20241604 1.00 TAS1R3 (0.39) TAS1R3TAS1R1TAS1R2CYP2C19CYP2C9
SCHEMBL6128220 0.93 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2CYP2C19CYP2C9
SCHEMBL21930790 0.88 TAS1R3 (0.42) TAS1R3TAS1R1TAS1R2CYP2C19CYP2C9
SCHEMBL2421273 0.86
SCHEMBL20640703 0.86
SCHEMBL3952688 0.86
SCHEMBL20257406 0.82 TRPV1 (0.40) TAS1R3TAS1R1TAS1R2KDM4ESMN1; SMN2
SCHEMBL6451931 0.82 TRPV1 (0.40) TAS1R3TAS1R1TAS1R2KDM4ESMN1; SMN2
SCHEMBL1300172 0.82 TAS1R3 (0.54) TAS1R3TAS1R1TAS1R2CYP2C19CYP2C9
SCHEMBL3723839 0.82 BLM (0.47) TAS1R3TAS1R1TAS1R2CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158406-A1 PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2024-05-16 US disclosed
EP-4342896-A1 PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2024-03-27 EP disclosed
WO-2024052702-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
WO-2024052692-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
WO-2023076598-A1 LIPID AMINES MODERNATX, INC. (US) 2023-05-04 WO disclosed
WO-2022242750-A1 PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2022-11-24 WO disclosed
US-10696639-B2 Heterocyclic compounds as HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2020-06-30 US disclosed
US-20190337902-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-11-07 US disclosed
EP-3551192-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2019-10-16 EP disclosed
WO-2018106519-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-06-14 WO disclosed
EP-2593461-B1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2016-08-17 EP disclosed
US-8637523-B2 Compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-28 US disclosed
EP-2593461-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION Bristol-Myers Squibb Company (US) 2013-05-22 EP disclosed
US-20120184565-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2012-07-19 US disclosed
WO-2012009309-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-19 WO disclosed
EP-1687275-A4 PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN MERCK & CO INC (US) 2009-01-14 EP disclosed
US-20070099950-A1 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain AGT SCIENCE LIMITED (GB) 2007-05-03 US disclosed
CN-1882546-A Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain MERCK & CO INC (US) 2006-12-20 CN disclosed
EP-1687275-A1 PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN Merck & Co., Inc. (US) 2006-08-09 EP disclosed
WO-2005051915-A1 PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN MERCK & CO., INC. (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696639-B2 Heterocyclic compounds as HIV protease inhibitors PREP, SERPINB1, PEPD TAS1R3 4720/4885TAS1R1 4657/4885TAS1R2 4823/4885
US-20190337902-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS PREP, SERPINB1, PEPD TAS1R3 4720/4885TAS1R1 4657/4885TAS1R2 4823/4885
US-20120184565-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP TAS1R3 4481/4885TAS1R1 4413/4885TAS1R2 4459/4885
US-20070099950-A1 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain PER2, CNR2, OPRD1 TAS1R3 2508/4885TAS1R1 2249/4885TAS1R2 1846/4885
US-20240158406-A1 PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE VHL, GLS2, GOT2 TAS1R3 4775/4885TAS1R1 4792/4885TAS1R2 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.